Beijing Taiyang Pharmaceutical Co. Ltd.

Using pioglitazone-metformin tablets (15 mg/500 mg) developed by Beijing Taiyang Pharmaceutical Co., Ltd. as the test formulation and pioglitazone-metformin tablets (trade name: Metakto LD®, 15 mg/500 mg) licensed by Takeda Pharmaceutical Co., Ltd. as the reference formulation, the pharmacokinetic parameters and relative bioavailability of the two formulations under single-dose administration in an empty stomach were investigated to evaluate their bioequivalence. The safety and tolerability of both formulations in healthy individuals were also evaluated.

The test formulation, pioglitazone-metformin tablets (15 mg/500 mg) developed by Beijing Taiyang Pharmaceutical Co., Ltd., and the reference formulation, pioglitazone-metformin tablets (Metact LD®, 15 mg/500 mg) from Takeda Teba Pharmaceuticals, were used. The pharmacokinetic parameters and relative bioavailability of the two formulations following single administration in the fasting and fed states were investigated to evaluate their bioequivalence. The safety and tolerability of the two formulations in healthy volunteers were also evaluated.

To study the relative bioavailability of ambroxol hydrochloride tablets (test preparation, 30 mg) produced by Beijing Taiyang Pharmaceutical Co., Ltd. and ambroxol hydrochloride tablets (reference preparation, 30 mg, trade name: SURBRONC) produced by Boehringer Ingelheim France in healthy subjects under fasting and fed conditions after a single oral administration, to evaluate the bioequivalence between the test preparation and the reference preparation, and to provide a basis for process optimization and clinical use of the test preparation.